Presurgical downstaging of vena caval tumor thrombus in advanced clear cell renal cell carcinoma using temsirolimus

被引：7

作者：

Sano, Futoshi ^{[1
]}

Makiyama, Kazuhide ^{[1
]}

Tatenuma, Tomoyuki ^{[1
]}

Sakata, Ryoko ^{[1
]}

Yamanaka, Hiroyuki ^{[1
]}

Fusayasu, Syusei ^{[1
]}

Nakayama, Takashi ^{[2
]}

Nakaigawa, Noboru ^{[1
]}

Yao, Masahiro ^{[1
]}

Kubota, Yoshinobu ^{[1
]}

机构：

[1] Yokohama City Univ, Grad Sch Med, Dept Urol, Yokohama, Kanagawa 2360004, Japan

[2] Saiseikai Yokohamashi Nanbu Hosp, Dept Pathol, Yokohama, Kanagawa, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2013年 / 20卷 / 06期

基金：

日本学术振兴会;

关键词：

presurgical setting; renal cancer; temsirolimus; tumor thrombus; INTERFERON-ALPHA; EXTENSION;

D O I：

10.1111/iju.12012

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A 63-year-old man presenting with a 7.2-cm right renal mass, an inferior vena cava tumor thrombus, and pulmonary metastases underwent renal mass biopsy that revealed clear cell renal cell carcinoma. Temsirolimus (25mg weekly) was given because of the extent of the disease and poor performance status, which resulted in a marked reduction in the tumor thrombus (from levelIII to levelI) after 20weeks of treatment. Subsequently, radical nephrectomy and tumor thrombectomy were carried out. Final pathological analysis confirmed the diagnosis of high-grade clear cell carcinoma (pT4N0M1). One year after initiation of temsirolimus therapy, the patient remained alive despite the presence of disease.

引用

页码：637 / 639

页数：3

共 10 条

[1] [Anonymous], 2010, GUID REN CELL CARC
[2] The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus
Cost, Nicholas G.
Delacroix, Scott E., Jr.
Sleeper, Joshua P.
Smith, Paul J.
Youssef, Ramy F.
Chapin, Brian F.
Karam, Jose A.
Culp, Stephen
Abel, E. Jason
Brugarolas, James
Raj, Ganesh V.
Sagalowsky, Arthur I.
Wood, Christopher G.
Margulis, Vitaly
[J]. EUROPEAN UROLOGY, 2011, 59 (06) : 912 - 918
[3] Harshman Lc, 2011, UROL ONCOL
[4] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Hudes, Gary
Carducci, Michael
Tomczak, Piotr
Dutcher, Janice
Figlin, Robert
Kapoor, Anil
Staroslawska, Elzbieta
Sosman, Jeffrey
McDermott, David
Bodrogi, Istvan
Kovacevic, Zoran
Lesovoy, Vladimir
Schmidt-Wolf, Ingo G. H.
Barbarash, Olga
Gokmen, Erhan
O'Toole, Timothy
Lustgarten, Stephanie
Moore, Laurence
Motzer, Robert J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) : 2271 - 2281
[5] Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi
Karakiewicz, Pierre I.
Suardi, Nazareno
Jeldres, Claudio
Audet, Pascale
Ghosn, Pierre
Patard, Jean-Jacques
Perrotte, Paul
[J]. EUROPEAN UROLOGY, 2008, 53 (04) : 845 - 848
[6] Surgery Insight: management of renal cell carcinoma with associated inferior vena cava thrombus
Karnes, R. Jeffrey
Blute, Michael L.
[J]. NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (06): : 329 - 339
[7] Prognostic factors for renal cell carcinoma with tumor thrombus extension
Klatte, Tobias
Pantuck, Allan J.
Riggs, Stephen B.
Kleid, Mark D.
Shuch, Brian
Zomorodian, Nazy
Kabbinavar, Fairooz F.
Belldegrun, Arie S.
[J]. JOURNAL OF UROLOGY, 2007, 178 (04) : 1189 - 1195
[8] Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289
[9] SURGICAL-TREATMENT OF RENAL-CANCER WITH VENA-CAVA EXTENSION
NEVES, RJ
ZINCKE, H
[J]. BRITISH JOURNAL OF UROLOGY, 1987, 59 (05): : 390 - 395
[10] Neoadjuvant Temsirolimus Effectiveness in Downstaging Advanced Non-Clear Cell Renal Cell Carcinoma
Rodriguez Faba, Oscar
Breda, Alberto
Rosales, Antonio
Palou, Joan
Algaba, Ferran
Maroto Rey, Pablo
Villavicencio, Humberto
[J]. EUROPEAN UROLOGY, 2010, 58 (02) : 307 - 310

← 1 →